A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease

Summary Individualised antiplatelet therapy and platelet function testing have attracted considerable clinical interest, but several aspects of test performance have not been thoroughly evaluated. We investigated repeatability and concordance of light transmission aggregometry (LTA) induced with arachidonic acid (AA) 1.0 mM, PFA-100® induced with collagen/epinephrine, multiple electrode aggregometry (MEA) induced with AA 0.5 or 0.75 mM and VerifyNow® Aspirin. Patients with stable coronary artery disease (n=43) and healthy individuals (n=21) were included. All tests were performed in duplicate at baseline in healthy individuals and in duplicate for four days in all study participants during aspirin treatment. Serum and urinary thromboxane metabolites were measured several times to evaluate cyclooxygenase-1 inhibition by aspirin. MEA was most sensitive for aspirin as treatment induced a 12-fold difference in AA-induced platelet aggregation. Coefficients of variation for duplicate measurements at baseline (0.4–12%), during aspirin treatment (3–46%) and for day-to-day variability (3–37%) differed markedly between tests and were lowest for VerifyNow®. The prevalence of aspirin low-responsiveness also differed between tests (0–9%) and the agreement was low: kappa≤0.21 for all tests compared with AA-induced LTA (reference test), which correlated best with VerifyNow® (r=0.43, p<0.001). Urinary thromboxane metabolites did not correlate with any platelet function test, whereas serum thromboxane correlated with VerifyNow® Aspirin (r=0.41, p=0.001). Overall, repeatability was moderate and the correlation between tests was low. VerifyNow® Aspirin proved most reproducible, and this was the only assay showing a significant positive correlation with serum thromboxane. This study demonstrated that conclusions based on platelet function testing strongly depend on the assay used.

[1]  E. Grove,et al.  The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease , 2009, Heart.

[2]  M. Wolzt,et al.  Cross validation of the Multiple Electrode Aggregometry , 2009, Thrombosis and Haemostasis.

[3]  E. Grove,et al.  Update on oral antiplatelet therapy: principles, problems and promises. , 2009, Future cardiology.

[4]  M. Lordkipanidzé,et al.  Response to aspirin in healthy individuals , 2009, Thrombosis and Haemostasis.

[5]  G. Davı̀,et al.  Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. , 2009, Thrombosis research.

[6]  E. Grove,et al.  Evaluation of aspirin response by Multiplate® whole blood aggregometry and light transmission aggregometry , 2009, Platelets.

[7]  E. Grove,et al.  Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. , 2008, Thrombosis research.

[8]  A. Michelson,et al.  Aspirin ‘resistance’: role of pre‐existent platelet reactivity and correlation between tests , 2008, Journal of thrombosis and haemostasis : JTH.

[9]  G. Lip,et al.  The role of aspirin in cardiovascular prevention: implications of aspirin resistance. , 2008, Journal of the American College of Cardiology.

[10]  A. Castelnuovo,et al.  PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients , 2008, Thrombosis and Haemostasis.

[11]  H. Mani,et al.  Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary , 2008, Journal of thrombosis and haemostasis : JTH.

[12]  W Scott Beattie,et al.  Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[13]  E. Grove,et al.  Monitoring aspirin therapy with the Platelet Function Analyzer‐100 , 2008, Scandinavian journal of clinical and laboratory investigation.

[14]  A. Kastrati,et al.  Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment , 2007, Thrombosis and Haemostasis.

[15]  A. Gori,et al.  Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy , 2007, Thrombosis and Haemostasis.

[16]  J. Eikenboom,et al.  Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[17]  A. Gori,et al.  Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. , 2007, American journal of clinical pathology.

[18]  C. Lau,et al.  Aspirin resistance and adverse clinical events in patients with coronary artery disease. , 2007, The American journal of medicine.

[19]  J. Turgeon,et al.  A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. , 2007, European heart journal.

[20]  M. Stegnar,et al.  Variation in Platelet Function Testing Has a Major Influence on Detection of Aspirin Resistance in Healthy Subjects , 2007, Pathophysiology of Haemostasis and Thrombosis.

[21]  Justin T. Newcomer,et al.  Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study , 2007, Circulation.

[22]  M. Cattaneo.  Laboratory detection of 'aspirin resistance': what test should we use (if any)? , 2007, European heart journal.

[23]  J. Segal,et al.  Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. , 2006, The American journal of cardiology.

[24]  Deepak L. Bhatt,et al.  Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. , 2006, American heart journal.

[25]  P. Hjemdahl,et al.  Dose- and time-dependent antiplatelet effects of aspirin , 2006, Thrombosis and Haemostasis.

[26]  P. Gurbel,et al.  Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. , 2005, Journal of the American College of Cardiology.

[27]  O. Hess,et al.  CLINICAL RESEARCH Interventional Cardiology Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy , 2005 .

[28]  J. Eikelboom,et al.  Aspirin resistance: position paper of the Working Group on Aspirin Resistance , 2005, Journal of thrombosis and haemostasis : JTH.

[29]  M. Cattaneo.  Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance , 2004 .

[30]  杨靓,et al.  Aspirin resistance , 2004 .

[31]  S. Steinhubl,et al.  Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[32]  C. Lau,et al.  Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. , 2004, Journal of the American College of Cardiology.

[33]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[34]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[35]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[36]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[37]  E. Topol,et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.

[38]  L. Feigen,et al.  Assessment of platelet function assays. , 1998, American heart journal.

[39]  M Ladjevardi,et al.  Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. , 1997, Thrombosis research.

[40]  G. FitzGerald,et al.  Paired analysis of urinary thromboxane B2 metabolites in humans. , 1987, Thrombosis research.

[41]  G. FitzGerald,et al.  Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. , 1987, Biochimica et biophysica acta.

[42]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[43]  G. FitzGerald,et al.  Estimated rate of thromboxane secretion into the circulation of normal humans. , 1986, The Journal of clinical investigation.

[44]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.

[45]  M. McMullin,et al.  Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease , 2008, Heart.

[46]  T. Haghfelt,et al.  Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. , 2007, Thrombosis research.

[47]  J. Drzewoski,et al.  Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. , 2004, Thrombosis research.